Asia-Pacific Blood and Marrow Transplantation Group (APBMT)

Annual Report 2007

Ayami Yoshimi
Yoshiko Atsuta
Ritsuro Suzuki
Yoshihisa Kodera

Secretariat Office of APBMT
Contents

Transplant Activity Survey
About Transplant Activity Survey-----------------------------------------------2
Results of the Transplant Activity Survey 2007 ---------------------------------5
Survey forms of the Transplant Activity Survey-----------------------------21
Contributors of the Transplant Activity Survey 2007 ------------------------24

World Wide Cooperation and Meetings----------------------------------------26

Annual Congresses of APBMT------------------------------------------------30

Minutes of the Business Meeting of APBMT
The 11th Congress in Nagoya-----------------------------------------------31
The 12th Congress in Beijing-----------------------------------------------33

Organization of APBMT------------------------------------------------------36
Transplant Activity Survey 2007

Background
The Asia Pacific Blood and Marrow Transplantation Group (APBMT) reached an agreement on the establishment of the “Asian Blood and Marrow Transplantation registry (Asian BMT registry)” at the 11th Congress of APBMT in Nagoya. Its data center was settled in the Department of HSCT Data Management, Nagoya University in Japan.

As the first step, we performed a “Transplant Activity Survey” to overview recent situations and trends of SCT in Asian countries. Using simple survey forms (see page 6-9), the number of all transplants performed until 2005 in Asian countries, according to indications, donor types, and stem cell sources, were collected. This kind of transplant activity survey has been performed in the European Group for Blood and Marrow Transplantation (EBMT) since 1990 (Gratwohl, et al, Bone marrow Transplantation 2007 39, 71-87).

Seven out of 12 countries/regions, participating in the APBMT have submitted their transplant activity data by October 15, 2007. The following figure shows how the data were collected.

From Japan and Malaysia the data was submitted through their national registry. In China, Hong Kong, and Iran, data were collected by Dr. Dao Pei Lu, Dr. Albert Lie and
Dr. Ardeshir Ghavamzadeh, respectively. In Vietnam and Singapore, the APBMT data center had direct contact with major transplant centers and received the data. The collected data of these 2 countries will be sent back to each country as their national data. Although the APBMT strongly encourages an establishment of a national registry in each Asian county, this way of collecting national data through the APBMT data center can be a temporal solution until a national registry will be available in each country.

**Findings**

The results in details are summarized later in this annual report. Data of 39,856 SCT from 408 centers were submitted. The absolute number of transplants has been steadily increasing in most of Asian countries/regions and was doubled in these 10 years. The data from 2005 showed that 4,598 transplants were performed in this year. The number of transplants has been increasing dramatically in China and in Iran.

The number of SCT for most of hematological malignancies has been increasing. The number of SCT for solid tumors has also been currently decreasing or stable. Hemoglobinopathy was one of the most common indications among non-malignant diseases in Asian countries except for China and Japan.

Of 4,598 SCT performed in 2005, 65% were allogeneic and 35% were autologous. The number of allogeneic SCT has been steadily increasing; meanwhile the number of autologous SCT has been recently stable. The distribution of related and unrelated donors (UD) differed widely among the countries. UD-SCT steadily increases in China, Japan and Hong Kong, but not in other countries. What’s interesting is that cord blood is widely used as a stem cell source in Asian countries, accounting for 35% of UD-SCT (data of 2005: 11% to 100%, in each country). Unrelated donor peripheral blood stem cell transplantation (UD-PBSCT) is not common in Asian countries. In the setting of SCT from a related donor, PBSCT is recently performed more frequently than bone marrow transplantation (BMT). 95% of stem cell source for auto-SCT is peripheral blood.

* The result was reported at the 12th APBMT Annual meeting in Beijing, September 2007 (A. Yoshimi)

**Summary**

This simple survey provided us interesting information about the current situation and trends of SCT in Asian countries. It is notable that the proportion of related and
unrelated donors differed widely among countries/regions. The proportion of each stem cell source of SCT from unrelated donors was also quite different in each country/region. Cord blood appeared to be an important stem cell source in most of the Asian countries.

**Future plan**

At the business meeting during the 12th Congress of APBMT in Beijing, the group agreed to continue the annual transplant activity survey in the future. Furthermore, a world-wide transplant activity survey is currently planned by the “Worldwide group for blood and marrow transplantation (WWBMT)” and APBMT will join this activity. Our goal is establishment of the Asian BMT registry. Hopefully the survey will be helpful to advance the Asian BMT Registry.
## Summary of Collected Data

<table>
<thead>
<tr>
<th></th>
<th>No. of reported SCT (all until 2005)</th>
<th>No of centers</th>
<th>No of SCT in 2005</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHN</td>
<td>1868</td>
<td>12*</td>
<td>427</td>
</tr>
<tr>
<td>HKG</td>
<td>1542</td>
<td>3</td>
<td>142</td>
</tr>
<tr>
<td>IRN</td>
<td>1374</td>
<td>2</td>
<td>279</td>
</tr>
<tr>
<td>JPN</td>
<td>33199</td>
<td>377</td>
<td>3519</td>
</tr>
<tr>
<td>MYS</td>
<td>1063</td>
<td>9</td>
<td>144</td>
</tr>
<tr>
<td>SGP</td>
<td>762</td>
<td>3</td>
<td>81</td>
</tr>
<tr>
<td>VNM</td>
<td>48</td>
<td>2</td>
<td>6</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>39,856</strong></td>
<td><strong>408</strong></td>
<td><strong>4,598</strong></td>
</tr>
</tbody>
</table>

CHN: China, HKG: Hong Kong, IRN: Iran, JPN: Japan, MYS: Malaysia, SGP: Singapore, VTN: Vietnam, SCT: Stem Cell Transplantation

* There are >33 centers in China and the data collection is ongoing.

## Increase of SCT in 10 Years Between 1995 and 2005

<table>
<thead>
<tr>
<th></th>
<th>0</th>
<th>5</th>
<th>10</th>
<th>15</th>
<th>20</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HKG</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IRN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>JPN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MYS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SGP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VNM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Allo vs Auto

All SCT until 2005

No of reported SCT

The Number of Allo-SCT

No of reported SCT
The Number of Auto-SCT

Allo vs Auto

SCT in 2005
Related vs Unrelated donor

All allo-SCT until 2005

No of reported SCT

The Number of SCT from Related Donor

No of reported SCT

Related donor
Unrelated donor
Stem Cell Source
- Unrelated Donor -

No of reported SCT

Stem Cell Source
- Unrelated Donor -

SCT in 2005

(*The data of IRN and VTN is the sum of all UR-SCT until 2005)
Stem Cell Source

- Auto SCT -

No of reported SCT

Disease Indication

All Transplants until 2005 in Each Country

[Bar charts and maps showing data]
Indications
2005

<table>
<thead>
<tr>
<th>CHN</th>
<th>HKG</th>
<th>IRN</th>
<th>JPN</th>
<th>MYS</th>
<th>SGP</th>
<th>VTN</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


Indications
All SCT until 2005

<table>
<thead>
<tr>
<th>CHN</th>
<th>HKG</th>
<th>IRN</th>
<th>JPN</th>
<th>MYS</th>
<th>SNG</th>
<th>VTN</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Acute Myelogenous Leukemia

Chronic Myelogenous Leukemia
## TRANSPLANT ACTIVITY SURVEY until 2005

### Indication

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AML</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CML</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MDS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other leukemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphoid malignancy (including LBL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multiple Myeloma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Solid tumor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aplastic anemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aquired Pure red cell anemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PNH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Congenital bone marrow failure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemoglobinopathy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other hematological disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EBV related disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemophagocytic syndrome</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Langerhans cell histiocytosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Autoimmune disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inherited metabolic disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary immune deficiencies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Others</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Classification

- **AML**: Define by WHO classification (BM blasts > 20%)
- **MDS**: Define by WHO classification (BM blasts ≤20%) e.g. RA, RCMD, RARS, RCMD-RS, RAEB1, RAEB2. Count MDS/MPD (eg. MDS/MPD unclassified, CMML, JMML) as MDS
- **Other leukemia**: e.g. ATL, CLL, myeloid NK precursor acute leukaemia
- **MPS**: e.g. Polycythaemia vera, essential thrombocythaemia, myelofibrosis
- **Congenital bone marrow failure**: e.g. Fanconi anemia, Dyskeratosis Congenita, Diamond–Blackfan anemia, congenital dyserythropoietic anemia, severe congenital neutropenia, myelodysplasia (WHIM syndrome)
- **Hemoglobinopathy**: e.g. beta-thalassemia, sickle cell disease
- **EBV related disorders**: e.g. CAEBV, hypersensitivity to mosquito bites
- **Inherited metabolic disease**: e.g. Mucopolysaccharidosis, Niemann–Pick dis., Gaucher dis., I-cell dis., Pompe dis., Krabbe dis., Metachromatic leukodystrophy, Adreno leukodystrophy, Osteopetrosis
- **Primary immune deficiencies**: e.g. SCID, Wiskott–Aldrich Syndrome, X-linked hyper IgM syndrome, chronic granulomatosis, Chediak–Higashi syndrome

Please fill the number of all transplanted patients for each indication and for each type of transplant.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>BM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PBSC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CB</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Others</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Family</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allogeneic</td>
<td>HLA id sibling</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>BM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PBSC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CB</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Others</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HLA non id*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>BM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PBSC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CB</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Others</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Twin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>BM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PBSC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CB</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Others</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Unrelated</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>BM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PBSC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CB</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Others</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Autologous</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>BM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PBSC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Others</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*any family member (matched or mismatched) other than HLA id sibling

Please send it back to the secretary's office of APBMT by FAX or EMAIL: Fax +81-52-719-1973 E-mail: office@apbmt.org
Please fill the number of transplanted patients for each indication and type of transplant in 2006.

<table>
<thead>
<tr>
<th>Indication</th>
<th>allogeneic</th>
<th>autologous</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HLA - id sibling</td>
<td>unrelated</td>
<td></td>
</tr>
<tr>
<td></td>
<td>family</td>
<td>non - id*</td>
<td>twin</td>
</tr>
<tr>
<td></td>
<td>BM</td>
<td>PB</td>
<td>CB</td>
</tr>
<tr>
<td>AML</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CML</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MDS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other leukemia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MPS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphoid malignancy (including LBL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multiple Myeloma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Solid tumor</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aplastic anemia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acquired Pure red cell anemia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PNH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Congenital bone marrow failure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemoglobinopathy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other hematological disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EBV related disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemophagocytic syndrome</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Langerhans cell histiocytosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Autoimmune disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inherited metabolic disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary immune deficiencies</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Others</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Classify the disease as followings:

- **AMLS**: Define by WHO classification (BM blasts>20%)
- **MDS**: Define by WHO classification (BM blasts<20%) (e.g. RA, ROMD, RARS, ROMD-RS, RAEB1, RAEB2, Count MDS/MPD (e.g. MDS/MPD unclassified, CMML, JMML) as MDS
- **Other leukemia**: eg. ATL, CLL, myeloid NK precursor acute leukemia
- **MPS**: eg. Polycythemia vera, essential thrombocythemia, myelofibrosis
- **Congenital bone marrow failure**: eg. Fanconanemia, Dyskeratosis Congenita, Diamond-Blackfan anemia, congenital dyserythropoetic anemia, severe congenital neutropenia, myelolathexis (WHIM syndrome)
- **Hemoglobinopathy**: eg. Shwachmann-Diamond Syndrome, congenital amegakaryocytic thrombocytopenia
- **EBV related disorders**: eg. Beta-thalassemia, sickle cell disease
- **Inherited metabolic disease**: eg. SCID, Wiskott-Aldrich Syndrome, X-linked hyper IgM syndrome, chronic granulomatosis, Chediak-Higashi syndrome
- **Primary immune deficiencies**: eg. SCID, Wiskott-Aldrich Syndrome, X-linked hyper IgM syndrome, chronic granulomatosis, Chediak-Higashi syndrome

*any family member (matched or mismatched) other than HLA id sibling

Please send it back to the secretary’s office of APBMT by FAX or EMAIL: Fax +81-52-719-1973  E-mail: office@apbmt.org
Contributors of Transplant Activity Survey 2007

The following centers/physicians contributed to the Transplant Activity Survey 2007.

**China (12 centers)**
Coordinator: Dr. Dao Pei Lu

The Third Affiliated Hospital of Zhongshan University  
DaoPei Hospital, Beijing  
Nankin Gurou Hospital  
Beijing Army General Hospital  
Institute of Hematology, Ha-erbin City  
The First Affiliated Hospital of Peking University  
Tongji Hospital, Institute of Hematology  
XiaQiano Hospital, Chougquing  
The Union Hospital Fujian Medical University  
South Hospital, Guang Zhou  
Institute of Hematology, Jiangsu Province  
Cancer Hospital, Chinese Academy of Medicine

*(There are more than 30 centers in China and the data collection is ongoing.)*

**Hong Kong (3 departments/centers)**
Coordinator: Dr. Albert Lie

Queen Mary Hospital (Adult)  
Queen Mary Hospital (Pediatric)  
Prince of Wales Hospital, Hong Kong

*(Dr. Lie collected the data of the 3 centers, which should cover >90% of SCT in HK)*

**Iran (2 centers)**
Dr. Ardeshir Ghavamzadeh

Teheran University of Medical Science  
Shiraz University
Singapore (3 departments/centers)

<table>
<thead>
<tr>
<th>Department/Center</th>
<th>Contact Person</th>
</tr>
</thead>
<tbody>
<tr>
<td>National University Hospital Singapore (Pediatrics)</td>
<td>Dr. Poh-Lin Tan</td>
</tr>
<tr>
<td>Singapore General Hospital</td>
<td>Dr. William Hwang</td>
</tr>
<tr>
<td>Childrens’ KK Hospital</td>
<td>Dr. Tan Ah Moy</td>
</tr>
</tbody>
</table>

(National Registry in preparation. 3 of the 4 major centers in Singapore send the data to APBMTG.)

Japan (National Registry)

Dr. Ayami Yoshimi, Dr. Yoshiko Atsuta, Dr. Ritsuro Suzuki, Dr. Yoshihisa Kodera

(377 centers, the Japan Society for Hematopoietic Cell Transplantation)

Malaysia (National Registry)

National Registry: Dr. Chan Lee Lee

(Pediatric 3 centers, Adults 6 centers, covering nearly 100% of SCT in Malaysia)

Vietnam (2 centers)

<table>
<thead>
<tr>
<th>Center</th>
<th>Contact Person</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood Transfusion and Hematology Center</td>
<td>Dr. Tran Van Binh</td>
</tr>
<tr>
<td>Hue Regional Hematology &amp; Blood Transfusion Center</td>
<td>Dr. Nguyen Ngoc Minh</td>
</tr>
</tbody>
</table>

(2 of 3 transplants centers in Vietnam sent the data to APBMT)
World Wide Cooperation and Meetings

APBMT has increased its activity of collaboration with other international registries including European Group for Blood and Marrow Transplantation (EBMT) and Center for International Blood and Marrow Transplant Research (CIBMTR) for the collection of common transplant data sets in the past year.

The world wide network “Worldwide group for blood and marrow transplantation (WWBMT)” was launched and the first meeting was organized by EBMT, CIBMTR, the World Marrow Donor Association (WMDA), and APBMT at Lyon in March, 2007.
Figure: Global collaboration with other registries

There was general consensus on the value of sharing ideas and resources and learning from each other without impacting on the independence of each group, developing a global outcomes registry to analyze progress in the field, and provide data for research and improve activities, and facilitating cooperative research.

The participants of WWBMT started working together to maintain a consensus on common data sets, to facilitate the development of regional registries and to develop universal patient, donor, and center ID numbers, and to initiate the global transplant activity survey.

Some members and secretariats of APBMT have attended following international meetings and telephone conferences to discuss on these issues.

1) Stem Cell Therapeutic Outcomes Database (SCTOD) Data Advisory Group Meeting during ASH meetings 2006

   Friday, December 8th, 2006
   8:00 AM -12:00 Noon EST
   Fantasia Room E and F, Contemporary Hotel
during ASH meeting, Orlando, Florida

Participants from APBMT members,
Dr. Yoshihisa Kodera, Dr. Ritsuro Suzuki, Dr. Ayami Yoshimi, Dr. Yoshiko Atsuta (Nagoya, Japan)
Dr. Dong Wook Kim (Soul, Korea)

2) Conference calls of the subcommittee of the SCTOD

During January 2006
   ● The Stem Cell Therapeutic Outcomes Database Subcommittee
   ● SCTOD Common Data Set Subcommittee
   ● SCTOD Cord Blood Bank Subcommittee
   ● SCTOD Emerging Indications Subcommittee
Participants from APBM members,
Dr. Yoshihisa Kodera, Dr. Ayami Yoshimi, Dr. Yoshiko Atsuta (Nagoya, Japan)
Dr. Don Wook Kim (Soul, Korea)

Dr. Minoko Takanashi and Dr. Tokiko Nagamura from Japan Cord Blood Bank Network also attended.

3) Stem Cell Therapeutic Outcomes Database (SCTOD) Data Advisory Group Meeting during ASBMT/CIBMTR BMT Tandem Meetings 2007

Kestone, February 8th-February 12th
February 8-12, Keystone, Colorado

Participants from APBMTG members,
Dr. Yoshihisa Kodera (Nagoya, Japan)

4) The first “Worldwide group for blood and marrow transplantation” (WWBMT) Meeting

18.00 – 19.15, Monday, 26 March, 2007
Room: Salon Tête d’Or C, Hilton Hotel
During EBMT 2007 Annual Meeting, Lyon

Website for WWBMT: www.wwbmt.org

Participants from APBMT members,
Dr. Yoshihisa Kodera, Dr. Ayami Yoshimi (Nagoya, Japan)
Dr. Ghavamzadeh Ardeshir (Tehran, Iran)
Dr. Shinichiro Okamoto (Tokyo, Japan)

Young physicians from India and Korea also attended the meeting.
Working group members of WWBMT from APBMT

1) Working Group for development of universal patient, donor and centre ID numbers
   Dr. Yoshihisa Kodera          Nagoya, Japan

   Dr. Yoshihisa Kodera          Nagoya, Japan
   Dr. Ayami Yoshimi            Nagoya, Japan
Annual Congresses of APBMT

1) Previous Congresses

<table>
<thead>
<tr>
<th>No</th>
<th>Year</th>
<th>City</th>
<th>President</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st</td>
<td>1990</td>
<td>Beijing</td>
<td>Cao, Lu Xian</td>
</tr>
<tr>
<td>2nd</td>
<td>1991</td>
<td>Nagoya</td>
<td>Masaoka, Tohru</td>
</tr>
<tr>
<td>3rd</td>
<td>1992</td>
<td>Osaka</td>
<td>Masaoka, Tohru</td>
</tr>
<tr>
<td>4th</td>
<td>1994</td>
<td>Fukuoka</td>
<td>Masaoka, Tohru</td>
</tr>
<tr>
<td>5th</td>
<td>1996</td>
<td>Seoul</td>
<td>Kim, Dong Jip</td>
</tr>
<tr>
<td>6th</td>
<td>1998</td>
<td>Taipei</td>
<td>Chen, Yao-Chang</td>
</tr>
<tr>
<td>7th</td>
<td>2000</td>
<td>Bangkok</td>
<td>Issaragrisil, Surapol</td>
</tr>
<tr>
<td>8th</td>
<td>2002</td>
<td>Mumbai</td>
<td>Advani, Suresh</td>
</tr>
<tr>
<td>9th</td>
<td>2004</td>
<td>Tehran</td>
<td>Ghavamzadeh, Ardeshe</td>
</tr>
<tr>
<td>10th</td>
<td>2005</td>
<td>Hangzhou</td>
<td>Lu, Dao-Pei</td>
</tr>
<tr>
<td>11th</td>
<td>2006</td>
<td>Nagoya</td>
<td>Kodera, Yoshihisa</td>
</tr>
</tbody>
</table>

2) Congress of 2007

12th Congress of APBMT
September 21-24, 2007, Beijing, China
President: Dr. Dao Pei Lu
Participants: 469
266 from local
203 from Hong Kong, Taipei, and other countries/regions

3) Next Congress

13th Congress of the APBMT
April 25-27, 2008, Taipei, Taiwan
President: Dr. Po-Min Chen
Co-President: Dr. Ji Hsiung Young
The Minutes of the Business Meeting of APBMTG in 2006

TIME: 10:00–12:00 October 27 (Friday), 2006
VENUE: Room “Satsuki”, 4th floor, Castle Plaza Hotel

Countries attended: China (Hong Kong), India, Iran, Japan, Korea, Malaysia, Pakistan, Taiwan, Thailand, Vietnam
Countries not attended: Indonesia, Singapore,

Attendee:
China: Daopei Lu (Beijing), He Huang (Hangzhou), Depei Wu (Suzhou), Kaiyan Liu (Beijing), Lu-Xian Cao (Beijing), Raymond Liang (Hong Kong), Albert Lie (Hong Kong), Jin-Lu Tang (Taipei)
India: Tapan K. Saikia (Mumbai), Alok Srivastava (Vellore),
Iran: Ghavamzadeh Ardeshir (Tehran)
Japan: Yoshihisa Kodera (Nagoya), Koichi Miyamura (Nagoya), Kazuhito Yamamoto (Nagoya), Ritsuro Suzuki (Nagoya), Yoshiko Atsuta (Nagoya), Yoshimi Ayami (Nagoya), Tohru Masaoka (Osaka), Akira Hiraoka (Osaka), Shigetaka Asano (Tokyo), Shinichiro Okamoto (Tokyo)
Korea: Hee Sook Park (Seoul), Dong-Wook Kim (Seoul), Kim, Chun Choo (Seoul), Kim, Dong Jip(Seoul), Huang, Tai-ju (Seoul),
Malaysia: Lin Hai Peng (Kuala Lumonr), Chan Lee Lee (Kuala Lumonr),
Pakistan: Khalil Ullah (Rawalpindi), Parvez Ahmed (Rawalpindi)
Taiwan: Po-Min Chen (Taipei)
Thailand: Issaragagrisil, Surapol (Bangkok)
Vietnam: Binh, Tran Van (Ho Chi Min)

Minutes

1. Report of the status of the 11th Congress of APBMTG 10:00 - 10:10
   The report from the congress secretary about the numbers of foreign attendees and domestic attendees, and the numbers of the presentations are the followings;
   Foreign attendee including invited speakers: 120
   Domestic attendee: 180
   Numbers of the presentation: Key-note addresses: 7
   Symposium and workshop: 38
   Oral presentations: 13
   Poster presentations: 45
   Luncheon seminars: 3
   Total: 106
2. Confirmation and addition of the members of the International Scientific Committee of APBMTG. Proposal of certain regulation for steering APBMTG  

10:10 - 10:40

It was confirmed that APBMTG was the abbreviation of Asia-Pacific Blood and Marrow Transplant Group. It was also confirmed that Australia, New Zealand and the USA would be treated as the honorable members of APBMTG. New members of the scientific committee were added from each country. The new committee members' list including their information such as e-mail address would be polished by the APBMTG office in the near future. To process every business of APBMTG more quickly, the creation of executive committee among the international committee was proposed and agreed. As the members of executive committee, Kodera Y (Nagoya), Dao-Pei L (Beijing), Issaragrisil S (Bangkok), Kim DJ (Seoul) and Ghavamzadeh A (Teheran) were nominated and agreed. It was decided that the executive committee should arrange the regulation of the APBMTG, the steering system and the regulation of Asian BMT Registry. The executive committee’s term was set to be 3 years.

3. Proposal and decision to set up the secretarial office for APBMTG  

10:40 - 11:00

After the discussion, it reached the agreement that the secretarial office for APBMTG and the data center for Asian BMT Registry would be set in Nagoya for a while. As the contact persons for the secretarial services for APBMTG and Asian BMT Registry, Koichi Miyamura, MD from Japanese Red Cross Nagoya First Hospital, Ritsuro Suzuki, MD, Yoshiko Atsuta, MD and Ayami Yoshimi, MD from Nagoya University were introduced.

The offices for secretarial services for APBMT group and APBMT registry were discussed to be the same office at the start for convenience. The separation of them will be considered in the future when their activities are more established. It was suggested to leave the name of the office to be open and to be decided in the executive committee. The secretarial office for APBMTG will make newsletters and send them to the members of APBMTG.

4. Proposal and decision to start the Asian BMT Registry  

11:00 – 11:30

The necessity of Asian BMT Registry was confirmed. It was also discussed and reached the agreement that the initial registration form should be a simple one and should be hopefully a form shared with the existed registration such as TED of CIBMTR or MED-A of EBMT. It was recommended that electronic device was used for the registration. Whether to start the Asian BMT registry as a national registry based registry or institution based registry was discussed. It was agreed that the executive committee will make the decision on it after the speeches and discussions in Symposium 1 in the afternoon of the same day.

5. Confirmation and decision of the 12th, 13th and 14th Congresses of APBMTG  

11:30 – 12:00

It was confirmed that the 12th congress would be organized by Prof. Dao Pei Lu in Beijing in 2007, the 13th congress would be organized by Prof. Po-Min Chen in Taipei in 2008, the 14th congress would be organized in Islamabad in 2009. The members of Scientific Committee from Seoul strongly proposed their ability to organize the congress in the near future, therefore it was agreed that every member kept the consideration about the appropriate timing for their organizing the congress.
Minutes of Business Meeting of the APBMTG in 2007

Time: 2100-2230, Sept. 22, 2007 (just after the Banquet in Crown Plaza Hotel)
Venue: No. 3 Meeting room, Crown Plaza Park View Wuzhou.

Countries / regions attended:
China, Hong Kong, Iran, Japan, Malaysia, Pakistan, Taiwan, Thailand

Countries / regions not attended:
Indonesia, India, Korea, Singapore, Vietnam

Attendee:
China
Daopei Lu (Beijing), He Huang (Hangzhou), Lu-Xian Cao (Beijing), Tong Wu(Beijing)

Hong Kong
Raymond Liang (Hong Kong), Albert Lie (Hong Kong)

Iran
Ardeshir Ghavamzadeh (Tehran)

Japan
Yoshihisa Kodera (Nagoya), Koichi Miyamura (Nagoya), Akira Hiraoka (Osaka), Shigetaka Asano (Tokyo), Tohru Masaoka(Osaka), Shinichiro Okamoto (Tokyo), Ritsuro Suzuki (Nagoya), Ayami Yoshimi (Nagoya), Yoshiko Atsuta (Nagoya)

Malaysia
Lin Hai Peng ( Kuala Lumpur), Chan Lee Lee (Kuala Lumpur)

Pakistan
Tahir Sultan Shamsi (Karachi), Tariq Mahmood Tariq (Rawalpindi), Salman Naseem Adil (Karachi)

Taiwan
Kai-Hsin Lin (Taipei), Po-Min Chen (Taipei), Jih-Luh Tang(Taipei), Tzeon-Jye Chiou(Taipei)

Thailand
Surapol Issaragagrisil (Bangkok)
Minutes

1. Report of the status of the 12th Congress of APBMT (Daopei Lu)
Dr. Dao-Pei has presented the status of the congress.

2. Confirmation of Regulatory Rules of APBMT (Y Kodera)
A draft of the regulatory rules of APBMT was reviewed. As for the membership, it was decided that the membership should be open to any physician or nurses who is engaged in hematopoietic stem cell transplantation. It was also agreed that the application form should include recommendation of one member of the scientific committee. Physicians will own regular membership, and nurses will own associate membership.
A need for application fee from the members was discussed. No conclusion was made, and this issue required further considerations, as well as benefits of the membership. The labor on fee collection was also indicated. This will be discussed once more at the next business meeting.

3. Annual Report and Transplant Activity Survey (A Yoshimi)
A draft of the Annual Report 2007 was presented by Dr. Yoshimi from the Secretary's office in Nagoya, Japan. Activity survey forms were submitted from China during the congress, which will be added to the final version of Annual Report 2007. “Number of transplant” in the Annual Report will be corrected to “Number of reported transplant”. Any comments or correction for the report should be send to the Secretary's office until October 16th, 2007.

4. APBMT Registry (Y Atsuta)
Basic survey items of the APBMT Registry were agreed to be shared with those of Transplant Essential Data (TED) form of the Center for International Blood and Marrow Transplant Research (CIBMTR) and Minimum Essential Data (MED) A form of the European Group of Blood and Marrow Transplantation (EBMT). TED/MED-A forms were revised recently (launch of revised MED-A was in July 2007, and revised TED has not been launched yet at the meeting time), and the revised MED-A forms were presented. Participation of APBMT members to the joint discussion of EBMT and CIBMTR was announced through the mailing list of Scientific Committee.
A need for additional survey items specific for APBMT Registry for research purpose will be discussed in the future.

5. Report on “World-Wide Group for Blood and Marrow Transplantation” (Y Kodera)
A movement of forming a network of BMT word-wide, “World-Wide Group for Blood and Marrow
Transplantation (WWBMT)” was reported. The first meeting was held during the EBMT meeting in March 2007, as reported in the mailing list of the Scientific Committee. Participation of the APBMT to the WWBMT was agreed.

6. New APBMTG Homepage (R Suzuki)
New APBMT Homepage was launched. There was a proposal that a part of registry report should be restricted to the members of APBMT. Further comments will be collected until the next business meeting.

7. List of Members, Mailing lists (A Yoshimi)
Two mailing lists, one for all the members of APBMT and the other for the Scientific Committee, are introduced in the Annual Report draft. Any corrections of the list of members and mailing addresses should be sent to the Secretary’s office until October 16th, 2007.

8. Future Annual Meetings
Next annual meeting, the 13th Congress of APBMT will be held in Taipei, organized by Prof. Chen, Po-Min. Place of the 14th Congress of APBMT in 2009 was discussed, without reaching an agreement. This should be decided in the next meeting at Taipei, because members of several countries were absent at this business meeting.

9. Other topics
The abbreviation of Asia-Pacific Blood and Marrow Transplantation Group was agreed to be “APBMT”, without “G”. The official name was confirmed to be “Asia-Pacific”, not “Asian-Pacific”. Discussions on the new logo of the APBMT were made, which was presented by the Secretary’s office via e-mail during the last year. A problem with the old logo that it did not cover the West Asia was mentioned. The new logo stands “A” and “P” for Asia-Pacific, and “bamboo” for a symbol of Asia. Other ideas for logo of the APBMT will be collected until the next business meeting 2008, and the final decision will be carried out.
Organization of APBMT (October 2007)

Executive committee
Kodera, Yoshihisa (Chairman, Japan)
Dao-Pei, Lu (China)
Ghavamzadeh, Ardeshir (Iran)
Issaragrisil, Surapol (Thailand)
Kim, Dong Jip (Korea)

Scientific Committee (other than executive committee)
Advani, Suresh H (India)  Kim, Dong Wook (Korea)
Asano, Shigetaka (Japan)  Kojima, Seiji (Japan)
Binh, Tran Van (Vietnam)  Liang, Raymond (Hong Kong)
Cao, Lu Xian (China)  Lie, Albert (Hong Kong)
Chan, Lee Lee (Malaysia)  Lin, Kai-Hsin (Taiwan)
Chen, Po-Min (Taiwan)  Masaoka, Tohru (Japan)
Chen, Yao-Chang (Taiwan)  Miyamura, Koichi (Japan)
Haipeng, Lin (Malaysia)  Okamoto, Shinichiro (Japan)
Harada, Mine (Japan)  Ouyang, Jian (China)
Hiraoka, Akira (Japan)  Saikia, Tapan K (India)
Huang, He (China)  Shamsi, Tahir Sultan (Pakistan)
Hwang, Tai-ju (Korea)  Tan, Patric (Singapore)
Junling, Hong (China)  Tang, Jin-Luh (China)

Secretariats
Suzuki, Ritsuro (Japan)
Yoshimi, Ayami (Japan)
Atsuta, Yoshiko (Japan)

Honorable Members
Atkinson, Kerry (USA)  Confer, Dennis (NMDP)
Horowitz, Marry (CIBMTR)  Niederwieser, Dietger (EBMT)
Gratwohl, Alois (EBMT)  Carter, John (New Zealand)
Hill, Geoffrey (Australia)  Goldman, John (EBMT)
Secretariat Office (Contact)
Department of HSCT Data Management
Nagoya University, School of Medicine
1-1-20 Daiko Minami, Higashi-ku, Nagoya 461-0047, Japan
TEL&FAX: +81-52-719-1973
E-mail: office@apbmt.org
Website: http://apbmt.org
APBMT Annual Report 2007
Vol. 1, October 2007

Ayami Yoshimi, Yoshiko Atsuta, Ritsuro Suzuki, Yoshihisa Kodera

Secretariat Office of APBMTG
Department of HSCT Data Management
Nagoya University, School of Medicine
1-1-20 Daiko Minami, Higashi-ku, Nagoya 461-0047, Japan